ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA

This study has been completed.
Study NCT00360243.   Last updated on June 17, 2008.   Information provided by Boehringer Ingelheim Pharmaceuticals
Please refer to this study by its ClinicalTrials.gov identifier: NCT00360243


Locations
United States, Alabama
Boehringer Ingelheim Investigational Site    
      Mobile, Alabama, United States
Boehringer Ingelheim Investigational Site    
      Huntsville, Alabama, United States
United States, Arizona
Boehringer Ingelheim Investigational Site    
      Tucson, Arizona, United States
United States, Arkansas
Boehringer Ingelheim Investigational Site    
      Jonesboro, Arkansas, United States
United States, California
Boehringer Ingelheim Investigational Site    
      Walnut Creek, California, United States
Boehringer Ingelheim Investigational Site    
      San Diego, California, United States
Boehringer Ingelheim Investigational Site    
      Tarzana, California, United States
Boehringer Ingelheim Investigational Site    
      Redding, California, United States
Boehringer Ingelheim Investigational Site    
      Stanford, California, United States
Boehringer Ingelheim Investigational Site    
      Carmichael, California, United States
Boehringer Ingelheim Investigational Site    
      Torrance, California, United States
Boehringer Ingelheim Investigational Site    
      Vista, California, United States
United States, Colorado
Boehringer Ingelheim Investigational Site    
      Wheatridge, Colorado, United States
Boehringer Ingelheim Investigational Site    
      Denver, Colorado, United States
United States, Connecticut
Boehringer Ingelheim Investigational Site    
      Hartford, Connecticut, United States
Boehringer Ingelheim Investigational Site    
      Farmington, Connecticut, United States
Boehringer Ingelheim Investigational Site    
      New London, Connecticut, United States
United States, Florida
Boehringer Ingelheim Investigational Site    
      Aventura, Florida, United States
Boehringer Ingelheim Investigational Site    
      Gainesville, Florida, United States
Boehringer Ingelheim Investigational Site    
      Stuart, Florida, United States
Boehringer Ingelheim Investigational Site    
      Orlando, Florida, United States
Boehringer Ingelheim Investigational Site    
      St. Petersburg, Florida, United States
Boehringer Ingelheim Investigational Site    
      Daytona Beach, Florida, United States
Boehringer Ingelheim Investigational Site    
      West Palm Beach, Florida, United States
Boehringer Ingelheim Investigational Site    
      Tampa, Florida, United States
Boehringer Ingelheim Investigational Site    
      Pembroke Pines, Florida, United States
Boehringer Ingelheim Investigational Site    
      New Port Richey, Florida, United States
Boehringer Ingelheim Investigational Site    
      Ft. Lauderdale, Florida, United States
United States, Georgia
Boehringer Ingelheim Investigational Site    
      Atlanta, Georgia, United States
Boehringer Ingelheim Investigational Site    
      Roswell, Georgia, United States
United States, Illinois
Boehringer Ingelheim Investigational Site    
      Chicago, Illinois, United States
Boehringer Ingelheim Investigational Site    
      Champaign, Illinois, United States
United States, Indiana
Boehringer Ingelheim Investigational Site    
      Indianapolis, Indiana, United States
United States, Kentucky
Boehringer Ingelheim Investigational Site    
      Lexington, Kentucky, United States
United States, Louisiana
Boehringer Ingelheim Investigational Site    
      Baton Rouge, Louisiana, United States
Boehringer Ingelheim Investigational Site    
      New Orleans, Louisiana, United States
United States, Maryland
Boehringer Ingelheim Investigational Site    
      St. Louis, Maryland, United States
United States, Massachusetts
Boehringer Ingelheim Investigational Site    
      Haverhill, Massachusetts, United States
United States, Michigan
Boehringer Ingelheim Investigational Site    
      Detroit, Michigan, United States
United States, Montana
Boehringer Ingelheim Investigational Site    
      Billings, Montana, United States
United States, New Jersey
Boehringer Ingelheim Investigational Site    
      Moorestown, New Jersey, United States
United States, New York
Boehringer Ingelheim Investigational Site    
      New York, New York, United States
Boehringer Ingelheim Investigational Site    
      Poughkeepsie, New York, United States
Boehringer Ingelheim Investigational Site    
      Purchase, New York, United States
Boehringer Ingelheim Investigational Site    
      Endwell, New York, United States
United States, North Carolina
Boehringer Ingelheim Investigational Site    
      Mount Airy, North Carolina, United States
Boehringer Ingelheim Investigational Site    
      Raleigh, North Carolina, United States
United States, Ohio
Boehringer Ingelheim Investigational Site    
      Mayfield Heights, Ohio, United States
Boehringer Ingelheim Investigational Site    
      Cincinnati, Ohio, United States
Boehringer Ingelheim Investigational Site    
      Columbus, Ohio, United States
Boehringer Ingelheim Investigational Site    
      Dayton, Ohio, United States
United States, Oklahoma
Boehringer Ingelheim Investigational Site    
      Tulsa, Oklahoma, United States
United States, Oregon
Boehringer Ingelheim Investigational Site    
      Medford, Oregon, United States
United States, Pennsylvania
Boehringer Ingelheim Investigational Site    
      Philadelphia, Pennsylvania, United States
Boehringer Ingelheim Investigational Site    
      West Reading, Pennsylvania, United States
United States, Rhode Island
Boehringer Ingelheim Investigational Site    
      Warwick, Rhode Island, United States
United States, South Carolina
Boehringer Ingelheim Investigational Site    
      Andreson, South Carolina, United States
Boehringer Ingelheim Investigational Site    
      Charleston, South Carolina, United States
United States, Tennessee
Boehringer Ingelheim Investigational Site    
      Nasville, Tennessee, United States
United States, Texas
Boehringer Ingelheim Investigational Site    
      Houston, Texas, United States
Boehringer Ingelheim Investigational Site    
      San Antonio, Texas, United States
Boehringer Ingelheim Investigational Site    
      Corpus Christi, Texas, United States
Boehringer Ingelheim Investigational Site    
      Dallas, Texas, United States
United States, Utah
Boehringer Ingelheim Investigational Site    
      Salt Lake City, Utah, United States
Boehringer Ingelheim Investigational Site    
      Sandy, Utah, United States
United States, Vermont
Boehringer Ingelheim Investigational Site    
      Burlington, Vermont, United States
United States, Virginia
Boehringer Ingelheim Investigational Site    
      Charlottesville, Virginia, United States
Boehringer Ingelheim Investigational Site    
      Richmond, Virginia, United States
Boehringer Ingelheim Investigational Site    
      Norfolk, Virginia, United States
United States, Washington
Boehringer Ingelheim Investigational Site    
      Bellevue, Washington, United States
Boehringer Ingelheim Investigational Site    
      Tacoma, Washington, United States
United States, Wisconsin
Boehringer Ingelheim Investigational Site    
      Milwaukee, Wisconsin, United States

Sponsors and Collaborators
Boehringer Ingelheim Pharmaceuticals

Investigators
Study Chair:     Boehringer Ingelheim     Boehringer Ingelheim Pharmaceuticals    


U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act
U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services



Links to all studies - primarily for crawlers